Barbara Boughton


Pembrolizumab/Ipilimumab Combo Effective in Advanced Melanoma

November 22nd 2015

A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.

Factors Affecting Dabrafenib/Trametinib Outcomes in Melanoma Identified

November 22nd 2015

In the largest-to-date analysis of treatment-naïve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.

Understanding BRAF Resistance Critical to Advancing Melanoma Care

November 21st 2015

Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.

James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations

November 20th 2015

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma

November 20th 2015

With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.

QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma

November 19th 2015

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Researchers Seek to Improve Responses With Checkpoint Inhibitors

November 19th 2015

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

New Treatments for Novel Targets Next Step in Immuno-Oncology Revolution

November 19th 2015

There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.